

EvaluatePharma®

European Drug Forecasts

Evaluate European Drug Forecasts to 2022: Real-world, country level historic product sales and consensus based forecasts.

Conduct European market sizing, R&D horizon scanning and price comparison utilising real world government and company reported sales data with country level, consensus based product forecasts to 2022.



European Market Sizing

Forecasts for key branded products

Model Future Pipeline Impact

Forecasts for full R&D pipeline

Government and Company Reported Drug Sales

Compare with audit based systems

Pricing

Perform comparative pricing analysis

Generic Market Analysis

Generic sales, volume & pricing

European Launch Dates

Launch dates for products in European countries

Single solution for business development and licensing, commercial and corporate strategy, consultants and investment banks



European Market Sizing

Forecasts for key branded drugs at a European country level – market value of over €100bn in 2022

- Conduct future market assessment
- Map future trends of key marketed drugs
- Profile in line products

Model Future Pipeline Impact

Full forecast pipeline for R&D products launching in Europe – market value €30bn

- Map key pipeline assets that are likely to launch by 2022 and measure impact
- Identify new medicines and how they impact therapy areas

Competitive Landscaping

Historical government and company reported sales data (EU 5 and other key markets)


- Compare product performance across key European markets
- Map uptake trends and drivers across European countries
- Understand drug launch timelines across 20 countries

Pricing Comparison Analysis Across Countries


Ex-factory pricing data for Germany, France, Italy, England, Poland, Spain and other key markets

- Perform comparative analysis across EU 6 countries for key products
- Use price/DDD benchmark to inform quick assessment of new assets


Europe Product Forecasts (€m):
Top 5 Brands in 2022 Anti-TNF Products




Europe R&D Product Forecasts:
Monoclonal Antibody Antineoplastics



Sales Market Share within Key Brands:
Monoclonal Antibody Antineoplastics



Manufacturer Price (France) € - Latest
(€) Monoclonal Antibody Antineoplastics



A pioneering methodology for European country level drug forecasts

Powered by Evaluate's industry standard consensus forecasts and broken out on a European country level using:

- European historical data – government and company reported
- Coupled with Evaluate's proprietary methodology inputs:
 - Estimated European launch timelines of R&D products
 - Analogue methodology to model forecast for R&D products
 - European uptake patterns and country launch timings
 - Expected European generic entry



Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support.

EvaluatePharma[®] delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance.

 [@EvaluatePharma](https://twitter.com/EvaluatePharma)

EvaluateMedTech[®] sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry.

 [@EvaluateMedTech](https://twitter.com/EvaluateMedTech)

EvaluateClinical Trials[®] delivers unique clinical trial intelligence expertly curated to efficiently analyse the global clinical trial landscape.

 [@EPClinicalTrial](https://twitter.com/EPClinicalTrial)

EP Vantage an award winning editorial team, provides daily commentary and analysis with fresh perspectives and insight into current and future industry trends.

 [@EPVantage](https://twitter.com/EPVantage)

Evaluate Custom Services provides customised solutions to help you access, analyse and manage the information you need to support effective decision-making.

The Evaluate services enable the life science community to make sound business decisions about value and opportunity.

www.evaluate.com

Evaluate Headquarters

Evaluate Ltd.
11-29 Fashion Street
London E1 6PX
United Kingdom
T +44 (0)20 7377 0800
F +44 (0)20 7539 1801

Evaluate North America

EvaluatePharma USA Inc.
15 Broad Street, Suite 401
Boston, MA 02109, USA
T +1 617 573 9450
F +1 617 573 9542

Evaluate Japan

Evaluate Japan KK
Akasaka Garden City 4F
4-15-1 Akasaka, Minato-ku
Tokyo 107-0052, Japan
T +81 (0)80 1164 4754